Managing blood thinners for cancer patients getting a catheter
Part of Cancer clinical trials.
This study tests a simple plan for stopping and restarting your blood thinner (DOAC) before and after getting a port or tunneled catheter. It aims to make the procedure safer for people with cancer who need blood thinners.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and take a blood thinner (DOAC) for a clot or atrial fibrillation.
- You have active cancer (diagnosed, treated, or spread within the last 6 months, or blood cancer not in remission).
- You are scheduled to get a port or tunneled catheter placed under X-ray guidance.
- You are willing to follow a plan for pausing and restarting your blood thinner around the procedure.
- You do not have a blood clot that happened in the last 21 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the safety of managing blood thinners (like apixaban or warfarin) around the time of cancer surgery or procedures. It aims to help doctors understand how to best handle these medications to reduce risks.
This study tests whether the blood thinner edoxaban can safely prevent blood clots caused by a central venous catheter in cancer patients. It may be an option if you have a catheter and are not already on blood thinners.
This study follows people who had a serious, non-surgical stomach/intestine bleed while taking a blood thinner, and looks at when and how they restart a DOAC (a type of blood thinner). It may help your care team reduce the risk of another bleed while still preventing stroke or blood clots.
This study tests whether a lower dose of the blood thinner apixaban (Eliquis) can safely prevent another blood clot in people with cancer who have a catheter-related clot in their upper arm or neck. It aims to find a balance between preventing clots and reducing bleeding risk.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This study looks at how well blood thinners work in people with cancer and a recent blood clot. It measures the risk of bleeding by checking certain blood clotting factors.
Hear when a new Anticoagulant-induced Bleeding trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.